Adrenocortical Positron Emission Tomography/PET-CT Imaging

PET Clinics

Volumn 2, Issue 3, 2007, Pages 331-339

  Kumar, Rakesh ^a   Alavi, Abass ^b   Fanti, Stefano ^c  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

11C etomidate and 11C metomidate; Adrenal masses; Adrenocortical imaging; FDG PET

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GA 68; 6 FLUORODOPA F 18; 6 FLUORODOPAMINE F 18; 6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131; ACETIC ACID C 11; CHOLESTEROL DERIVATIVE; ETOMIDATE C 11; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLESTER F 18; IODINE 131; IODOCHOLESTEROL I 131; METOMIDATE C 11; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADRENAL CORTEX DISEASE; ADRENAL CORTEX TUMOR; ADRENAL METASTASIS; ADRENAL TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW;

EID: 64749102384     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2008.04.002     Document Type: Review

References (37)

1. Gross M.D., Korobkin M., Hussain H., et al. Adrenal gland imaging. In: Jameson J.L., and DeGroot L.J. (Eds). Endocrinology. 5th edition (2005), WB Saunders, Philadelphia 2425-2453
2. Hussain S., Belldegrun A., Seltzer S.E., et al. Differentiation of malignant from benign adrenal masses: Predictive indices on computed topography. AJR Am J Roentgenol 144 (1985) 61-65
3. Korobkin M. CT characterization of adrenal masses: the time has come. Radiology 217 (2000) 629-632
4. Berland L.L., Koslin D.B., Kennedy P.J., et al. Differentiation between small benign and malignant adrenal masses with dynamic incremented CT. AJR Am J Roentgenol 151 (1988) 95-101
5. Korobkin M., Brodeur F.J., Yutzy G.G., et al. Differentiation of adrenal adenomas from non adenomas using CT attenuation values. AJR Am J Roentgenol 166 (1996) 531-536
6. Fishman E.K., Deutch B.M., Hartman D.S., et al. Primary adrenocortical carcinoma: CT evaluation with clinical correlation. AJR Am J Roentgenol 148 (1987) 531-535
7. Paivansalo M., Lahde S., Merikanto J., et al. Computed tomography in primary and secondary adrenal tumors. Acta Radiol 29 (1988) 519-522
8. Korobkin M., Brodeur F.J., Francis I.R., et al. CT time attenuation washout curves of adrenal adenomas and non adenomas. AJR Am J Roentgenol 170 (1998) 747-752
9. Mitchell D.G., Crovello M., Matteucci T., et al. Benign adrenocortical masses: diagnosis with chemical shift MR imaging. Radiology 185 (1992) 345-351
10. Outwater E.K., Siegelman E.S., Huang A.B., et al. Adrenal masses: Correlation between CT attenuation value and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences. Radiology 200 (1996) 749-752
11. Haider M.A., Ghai S., Jhaveri K., et al. Chemical shift MR imaging of hyper attenuating (>10 HU) adrenal masses: does it still have a role?. Radiology 231 (2004) 711-716
12. Schwartz L.H., Panicek D.M., Koutcher J.A., et al. Adrenal masses in patients with malignancy: prospective comparison of echo-planar, fast spin echo, and chemical shift MR imaging. Radiology 197 (1995) 421-425
13. Gross M.D., Shapiro B., Bouffard J.A., et al. Distinguishing benign from malignant adrenal masses. Ann Intern Med 109 (1988) 613-618
14. Gross M.D., Avram A., Fig L.M., et al. PET in the diagnostic evaluation of adrenal tumors. Q J Nucl Med Mol Imaging 51 (2007) 272-283
15. Lumachi F., Zucchetta P., Marzola M.C., et al. Usefulness of CT scan, MRI and radiocholesterol scintigraphy for adrenal imaging in Cushing's syndrome. Nucl Med Commun 23 (2002) 469-473
16. Bergström M., Juhlin C., Bonasera T.A., et al. PET imaging of adrenal cortical tumors with the 11-hydroxylase tracer 11C-metomidate. J Nucl Med 41 (2000) 275-282
17. Bergström M., Bonasera T.A., Lu L., et al. In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med 39 (1998) 982-989
18. Kumar R., Nadig M., and Chauhan A. Positron emission tomography: clinical application in oncology: part I. Expert Rev Anticancer Ther 5 (2005) 1079-1094
19. Kumar R., Basu S., Anand V., et al. FDG-PET imaging for assessing inflammation and infection. Clin Microbiol Rev 21 (2008) 209-224
20. Hennings J., Lindhe O., Bergström M., et al. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 91 (2006) 1410-1414
21. Khan T.S., Sundin A., Juhlin C., et al. 11C-metomidate imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 30 (2003) 403-410
22. Kumar R., Xiu Y., Mavi A., et al. FDG-PET imaging in primary bilateral adrenal lymphoma: A case report and review of literature. Clin Nucl Med 30 (2005) 222-230
23. Zettinig G., Mitterhauser M., Wadsak W., et al. Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate. Eur J Nucl Med Mol Imaging 31 (2004) 1224-1230
24. Tenenbaum F., Groussin L., Foehrenbach H., et al. 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patients. Eur J Endocrinol 150 (2004) 789-792
25. Minn H., Salonen A., Friberg J., et al. Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. J Nucl Med 45 (2004) 972-979
26. Ng L., and Libertino J.M. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 169 (2003) 5-11
27. Becherer A., Vierhapper H., Potzi C., et al. FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm 16 (2001) 289-295
28. Leboulleux S., Dromain C., Bonniaud G., et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 91 (2006) 920-925
29. Mackie G., Shulkin B., Ribeiro R., et al. Use of 18F]Fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 91 (2006) 2665-2671
30. Blake M.A., Slattery J., Kalra M.K., et al. Adrenal lesions: characterisation with fused PET/CT image in patients with proved or suspected malignancy-initial experience. Radiology 238 (2006) 970-977
31. Kumar R., Xiu Y., Yu J.Q., et al. F18 -FDG PET in Evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 45 (2004) 2058-2062
32. Jana S., Zhang T., Milstein D.M., et al. FDG-PET and CT characterization of adrenal lesions in cancer patients. Eur J Nucl Med Mol Imaging 33 (2006) 29-35
33. Kumar R., Anand V., and Jana S. Adrenal Lesions: role of computed tomography, magnetic resonance imaging, 18fluorodeoxyglucose-positron emission tomography, and positron emission tomography/computed tomography. In: Hayat M.A. (Ed). Instrumentation and Applications. Cancer Imaging vol. 2 (2008), Elsevier, Philadelphia 269-279
34. Patel S.M., Lingam R.K., Beaconsfield T.I., et al. Role of radiology in the management of primary aldosteronism. Radiographics 27 4 (2007) 1145-1157
35. Hedeland H., Ostberg G., and Hokfelt B. On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes. Acta Med Scand 184 (1968) 211-214
36. Hennings J., Hellman P., Ahlström H., et al. Computed tomography, magnetic resonance imaging and (11)C-metomidate positron emission tomography for evaluation of adrenal incidentalomas. Eur J Radiol (2007 Dec 13) [Epub ahead of print]
37. Wadsak W., Mitterhauser M., Rendl G., et al. [18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. Eur J Nucl Med Mol Imaging 33 (2006) 669-672